Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    169
    ...
ATC Name B/G Ingredients Dosage Form Price
J01AA08 VULGA XR G Minocycline - 55mg 55mg Tablet, film coated 1,983,512 L.L
J05AG03 STOVIRENZ G Efavirenz - 600mg 600mg Tablet, film coated 6,857,456 L.L
L01EA01 GLIMATINIB BENTA 400 G Imatinib (mesylate) - 400mg 400mg Tablet, film coated 38,254,090 L.L
M01AB05 OLFEN-100 SR G Diclofenac sodium - 100mg 100mg Capsule, prolonged release 503,941 L.L
N01AB06 ISOFLURANE HIKMA G Isoflurane - Volatil liquid 1,583,046 L.L
N03AX12 GABAMOX G Gabapentin - 300mg 300mg Capsule, hard 1,108,670 L.L
P01AB01 RAMAZOL G Metronidazole - 500mg 500mg Tablet 216,359 L.L
A04AA01 VOMITRON G Ondansetron (HCl) - 4mg/5ml 4mg/5ml Solution 304,604 L.L
A10BD08 VLUDIN MET G Metformin HCl - 1000mg, Vildagliptin - 50mg Tablet, film coated 735,914 L.L
B01AC06 ASPIPHAR G Acetylsalicylic acid - 100mg 100mg Tablet, enteric coated 134,384 L.L
B05BB02 2.5% DEXTROSE 0.45% SODIUM CHLORIDE INJECTION G Dextrose,H2O - 2.5g/100ml, Sodium chloride - 0.45g/100ml Injectable solution 224,090 L.L
C01CA24 ADRENALINE AGUETTANT G Adrenaline - 0.1mg/ml 0.1mg/ml Injectable solution 13,990,891 L.L
C09AA01 ORBACE G Captopril - 25mg 25mg Tablet 522,179 L.L
J01DI02 ZINFORO G Ceftaroline fosamil - 600mg 600mg Injectable powder for concentrate for solution 44,995,862 L.L
L01EA01 IMATINIB GP PHARM G Imatinib - 400mg 400mg Tablet, coated 26,083,945 L.L
M01AB05 TRATUL RETARD G Diclofenac Sodium - 100mg 100mg Tablet, film coated 866,778 L.L
N03AX12 GABANET 300 G Gabapentin - 300mg 300mg Capsule 1,380,126 L.L
R05X BROMEX G Pyrilamine Maleate (Mepyramine) - 12.5mg/5ml, Bromhexine HCl - 4mg/5ml Elixir 250,851 L.L
V03AC03 DEFERASIROX ARROW G Deferasirox - 180mg 180mg Tablet 13,280,846 L.L
A04AA01 NOZAMET G Ondansetron - 4mg 4mg Film, orodispersible 3,234,181 L.L
B05BB02 2.5% DEXTROSE 0.45% SODIUM CHLORIDE INJECTION G Dextrose,H2O - 2.5g/100ml, Sodium chloride - 0.45g/100ml Injectable solution 150,543 L.L
C01CA26 EPHEDRINE AGUETTANT G Ephedrine HCl - 30mg/ml 30mg/ml Injectable solution 614,136 L.L
C09AA01 APO-CAPTO G Captopril - 50mg 50mg Tablet, scored 1,752,371 L.L
C10AA01 SIMVASTATIN NORMON G Simvastatin - 10mg 10mg Tablet, film coated 264,737 L.L
J01AA12 TAGIX G Tigecycline - 50mg 50mg Injectable lyophilised powder for solution 2,436,386 L.L
L01EA01 IMATINIB NEAPOLIS G Imatinib - 400mg 400mg Tablet, film coated 36,046,335 L.L
M01AB05 CLOREN ADULTS G Diclofenac sodium - 100mg 100mg Suppository 598,970 L.L
N03AX12 GABAPENTINE ARROW GENERIQUES G Gabapentin - 300mg 300mg Capsule 1,342,499 L.L
P01AB01 METROLAG G Metronidazole - 250mg 250mg Tablet 130,353 L.L
R05X COLDIN G Caffeine - 30mg, Noscapine - 10mg, Pseudoephedrine HCl - 30mg, Pyrilamine maleate (Mepyramine) - 15mg, Paracetamol - 300mg Capsule 386,515 L.L
    ...
    169
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025